अApnaFunda
Menu

ALBERT DAVID LTD (ALBERTDAVD)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.46 / 100
Profitability 21Growth 18Balance sheet 100

Passes these screensValue Pick

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹800.9 latest close · +11.3% over the last 90 sessions

₹700₹800₹900Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹700₹800₹900Jul 3Sep 4Nov 9

₹800.9 month-end · +1.0% over 12 months

₹600₹700₹800₹900Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹600₹700₹800₹900Nov '25May '26Nov '26

₹800.9 month-end · −24.4% over 3 years

₹500₹1,000₹1,500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹500₹1,000₹1,500Nov '23May '25Nov '26

₹800.9 month-end · +113.4% since Jan '19

₹500₹1,000₹1,500Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹500₹1,000₹1,500Jan '19Dec '22Nov '26

52-week range ₹579.90 to ₹931.85 · 1-year volatility 33.8%

Was the rally earned?

+1%share price, 1 yearRoughly flat
  • The share price was roughly flat over 1 year (+1%).
  • The share count fell 10%.
Net profit growth: +118 pts. Points of the price return explained by net profit growing (or shrinking).+118 ptsNet profit growthP/E change: −127 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−127 ptsP/E changeShare count change: +11 pts. Points of the price return explained by the share count changing. More shares count against the price.+11 ptsShare count changeShare price: +1%+1%Share priceNet profit growth: +118 pts. Points of the price return explained by net profit growing (or shrinking).+118ProfitP/E change: −127 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−127P/EShare count change: +11 pts. Points of the price return explained by the share count changing. More shares count against the price.+11SharesShare price: +1%+1%Share price
Net profit growth+118 ptsNet profit rose about 223%, which lifts the price.
P/E change-127 ptsThe P/E fell from 72.0x to 20.3x, which lowers the price.
Share count change+11 ptsShare count fell 10%, which lifts the price.
-24%share price, 3 yearsEarnings-driven

Mostly earnings.

  • Per-share earnings took off 41 points, while the multiple moved less (P/E 16.7x to 20.3x).
  • The share count barely moved.
Net profit growth: −41 pts. Points of the price return explained by net profit growing (or shrinking).−41 ptsNet profit growthP/E change: +17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+17 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: −24%−24%Share priceNet profit growth: −41 pts. Points of the price return explained by net profit growing (or shrinking).−41ProfitP/E change: +17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+17P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: −24%−24%Share price
Net profit growth-41 ptsNet profit fell about 37%, which lowers the price.
P/E change+17 ptsThe P/E rose from 16.7x to 20.3x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+38%share price, 5 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 14.9x to 20.3x); per-share earnings added 2 points.
  • The share count barely moved.
Net profit growth: +3 pts. Points of the price return explained by net profit growing (or shrinking).+3 ptsNet profit growthP/E change: +36 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+36 ptsP/E changeShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1 ptsShare count changeShare price: +38%+38%Share priceNet profit growth: +3 pts. Points of the price return explained by net profit growing (or shrinking).+3ProfitP/E change: +36 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+36P/EShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1SharesShare price: +38%+38%Share price
Net profit growth+3 ptsNet profit rose about 3%, which lifts the price.
P/E change+36 ptsThe P/E rose from 14.9x to 20.3x, which lifts the price.
Share count change-1 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-65.4%not yet recovered
1-year volatility33.8%annualised

Drawdown from peak

0%−20%−40%−60%2020202120222023202420252026−64.1% 0%−20%−40%−60%2020202220242026−64.1%
Largest drawdowns

-65.4% (2024-09 peak to 2026-03 low, not yet recovered)

-48.8% (2020-02 peak to 2020-03 low, recovered 2021-07)

-34.8% (2019-05 peak to 2019-08 low, recovered 2020-01)

Is it expensive against its own past and its peers?

20.3xP/E todayNear its historic high
Against its own history81st percentile
CheapestMedian 12.6xDearest

Usual range 8.6x to 25.5x since 2019-01.

Against Health Technology20.3x vs 37.0x
This company
20.3x
Sector median
37.0x

45% below the Health Technology median.

6.8x30.3x53.7x77.1xJan '19Aug '20Mar '22Oct '23May '25Nov '266.8x30.3x53.7x77.1xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE11th▼ 7 pts vs a year ago
  • Op. margin31st▲ 26 pts vs a year ago
  • Revenue growth49th▲ 40 pts vs a year ago
  • EPS growth96th▲ 91 pts vs a year ago
  • Debt/equity ↓71st▼ 9 pts vs a year ago
  • Cash cycle ↓62ndflat vs a year ago
  • P/E ↓77th▲ 61 pts vs a year ago
  • 12M momentum43rd▲ 23 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~11%annual earnings growth implied by the price

At a P/E of 14.4x, the price would imply about 10.5%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹800.90
P/E
20.3x
ROCE
1.0%
Market Cap
₹458 cr
Revenue (TTM)
₹364 cr
P/S
1.3x
P/B
1.2x
ROE
5.8%
Operating Margin
10.0%
Debt / Equity
0.1x
Promoter Holding
62.2%
12M Momentum
1.0%

52-week range

₹579.90₹931.85
63% of the way from its 52-week low to its high

Price risk

1Y volatility
33.8%
Beta vs sector
1-year daily
0.61

Balance sheet & cash

Interest cover
operating profit ÷ interest
10.7x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.11x
low
Share count, 1Y
unchanged

Are profits backed by cash?

3 of 7checks within range2 beyond a threshold
Other income reliance46%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 46.4%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate13%Near threshold

Median quarterly effective tax rate over about 2.5 years: 13.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.11xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.11x (cash from operations ₹10 cr, net profit ₹91 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+7 daysWithin range

Debtor days are above the median of the previous three fiscal years by 7 days (37 vs 30). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress21% of fixed assetsWithin range

Capital work-in-progress is 21% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+6 days / 2 yrsWithin range

Days payable changed by +6 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, institutional and promoter holdings were broadly unchanged.
  • The number of shareholders rose from 10,041 to 13,155 (+31%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters62.0%62.2%+0.2 pts
FIIs0.7%0.6%-0.1 pts
DIIs1.7%1.6%0.0 pts
Public and others35.6%35.6%0.0 pts

Number of shareholders

13,155shareholders+31% since Dec '23
10k12k14k15k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 10,041
Mar '24: 11,266
Jun '24: 12,349
Sep '24: 13,590
Dec '24: 14,830
Mar '25: 15,304
Jun '25: 15,070
Sep '25: 14,666
Dec '25: 13,967
Mar '26: 13,555
Jun '26: 13,155
 10k12k14k15k Dec '23Dec '24Dec '25Jun '26
Dec '23: 10,041
Mar '24: 11,266
Jun '24: 12,349
Sep '24: 13,590
Dec '24: 14,830
Mar '25: 15,304
Jun '25: 15,070
Sep '25: 14,666
Dec '25: 13,967
Mar '26: 13,555
Jun '26: 13,155

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+3.5%typical 12-month return vs the marketAbove the base rate
  • We found 50 past situations where a non-financial company looked like ALBERT DAVID LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −22% to +27% vs the market, against −5% for all non-financial companies in the same months.
  • The analogs' median sat above that base rate (gap +8.0%, 80% range +0.6% to +9.3%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
ELIN · Oct 2025: −63.5% vs market
HUHTAMAKI · Jan 2021: −50.5% vs market
HERANBA · Oct 2024: −39.8% vs market
PLASTIBLEN · Nov 2023: −39.0% vs market
TVTODAY · Jul 2024: −37.3% vs market
LINC · May 2025: −36.1% vs market
GHCLTEXTIL · Oct 2024: −28.9% vs market
MAHEPC · Jul 2025: −28.9% vs market
IRMENERGY · Sep 2025: −28.6% vs market
CLEDUCATE · Nov 2024: −27.4% vs market
UNIDT · Mar 2025: −27.3% vs market
ZODIACLOTH · Jul 2023: −26.5% vs market
SMARTLINK · Mar 2023: −22.3% vs market
JTEKTINDIA · May 2024: −22.0% vs market
BHAGERIA · Sep 2024: −21.7% vs market
IMPAL · Jan 2020: −19.1% vs market
MMP · Jun 2023: −6.5% vs market
ANDHRAPAP · Sep 2025: −6.3% vs market
ORIENTCER · Sep 2023: −5.5% vs market
FMGOETZE · Oct 2022: −3.7% vs market
HMVL · May 2023: −3.0% vs market
MANALIPETC · Oct 2025: −2.3% vs market
SUNFLAG · Feb 2025: −1.0% vs market
VSSL · Sep 2024: +2.0% vs market
PRECAM · Apr 2023: +3.2% vs market
BANARBEADS · Oct 2024: +3.8% vs market
HINDCOMPOS · Jul 2023: +4.6% vs market
IFGLEXPOR · Jul 2023: +4.9% vs market
TNPETRO · Aug 2025: +6.0% vs market
RAMCOIND · Feb 2025: +7.3% vs market
GUJAPOLLO · Dec 2023: +8.6% vs market
ALMONDZ · Mar 2020: +9.3% vs market
BBL · Jan 2024: +13.9% vs market
NAVNETEDUL · Jul 2022: +15.6% vs market
STYRENIX · Jul 2024: +17.8% vs market
SREEL · Oct 2025: +18.3% vs market
PPAP · Jul 2020: +25.0% vs market
DTIL · May 2020: +27.3% vs market
TTKHLTCARE · Nov 2022: +31.1% vs market
GENUSPAPER · Jan 2022: +36.5% vs market
BALMLAWRIE · Dec 2022: +37.8% vs market
ASHIMASYN · Oct 2023: +42.9% vs market
GALLANTT · Jun 2020: +43.0% vs market
EVERESTIND · Apr 2021: +48.2% vs market
CHEMBOND · Dec 2022: +70.2% vs market
TDPOWERSYS · Apr 2021: +75.8% vs market
DBCORP · Aug 2022: +97.5% vs market
IOLCP · Sep 2025: +100.4% vs market
NAHARPOLY · Mar 2020: +136.4% vs market
GABRIEL · Sep 2024: +148.3% vs market
Similar setups +3.5%All companies −4.5%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median
+3.5%
All companies' median
−4.5%
Beat the market
54% vs 45%

50 past situations · 50 companies · 35 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
VSSL
Non-Energy Minerals		 Sep 2024 26x— +53%−6% +2%
RAMCOIND
Non-Energy Minerals		 Feb 2025 16x3% +4%−28% +7%
LINC
Consumer Non-Durables		 May 2025 24x— +8%−22% −36%
HMVL
Consumer Services		 May 2023 12x3% +16%−2% −3%
HINDCOMPOS
Producer Manufacturing		 Jul 2023 20x4% +38%−1% +5%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CHEMBOND
Process Industries		 Dec 2022 23x7% +14%−11% +70%
GHCLTEXTIL
Process Industries		 Oct 2024 31x6% +41%−10% −29%
GABRIEL
Producer Manufacturing		 Sep 2024 38x— +56%−6% +148%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/S and drawdown from 12-month high. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ALBERT DAVID LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

30 events since Jun '22

  1. OctResultsYear-on-year EPS growth turned positive.
  2. SepResultsEPS (TTM) turned positive.
  3. SepPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  4. JunResultsEPS (TTM) turned negative.
  5. JunPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  6. JunDividendDividend payout cut from 17% to -192% of profit.
  7. MarResultsEPS (TTM) turned positive.
  8. MarPriceFell 65% from the Sep 2024 peak to the Mar 2026 low.
Show 22 earlier events
  1. MarValuationP/E crossed above the 90th percentile of its own history to date (34.9x).
  2. MarPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  3. DecResultsEPS (TTM) turned negative.
  4. JunResultsYear-on-year EPS growth turned negative.
  5. JunValuationP/E crossed above the 90th percentile of its own history to date (27.8x).
  6. JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the top quartile).
  7. MarPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  8. FebValuationP/E fell below the 10th percentile of its own history to date (7.1x).
  9. DecResultsRevenue (TTM) reached a new high of ₹364 cr.
  10. SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  11. AugPriceRegained the 2024-01 peak, 5 months after the low.
  12. JunResultsRevenue (TTM) reached a new high of ₹362 cr.
  13. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  14. MarPriceFell 34% from the Jan 2024 peak to the Mar 2024 low.
  15. NovValuationP/E crossed above the 90th percentile of its own history to date (16.7x).
  16. JulPriceRegained the 2022-01 peak, 13 months after the low.
  17. JunResultsRevenue (TTM) reached a new high of ₹341 cr.
  18. JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  19. MarValuationP/E fell below the 10th percentile of its own history to date (8.3x).
  20. JunPriceFell 30% from the Jan 2022 peak to the Jun 2022 low.
  21. JunValuationP/E fell below the 10th percentile of its own history to date (8.4x).
  22. JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1120.3x₹364 cr5.8%1.0%0.1x
2026-1019.3x₹364 cr5.9%1.0%0.1x
2026-0922.1x₹364 cr5.9%1.0%0.1x
2026-08—₹334 cr-0.4%1.0%0.1x
2026-07—₹334 cr-0.4%1.0%0.1x
2026-06—₹334 cr-0.4%1.0%0.1x
2026-0542.1x₹323 cr2.5%6.0%0.0x
2026-0442.5x₹323 cr2.5%6.0%0.0x
2026-0334.9x₹323 cr2.5%6.0%0.0x
2026-02—₹316 cr-3.6%6.0%0.0x
2026-01—₹316 cr-3.6%6.0%0.0x
2025-12—₹316 cr-3.6%6.0%0.0x
2025-1172.0x₹327 cr1.8%6.0%0.0x
2025-1077.1x₹327 cr1.8%6.0%0.0x
2025-0970.9x₹327 cr1.8%6.0%0.0x
2025-0826.6x₹345 cr4.6%6.0%0.0x
2025-0729.6x₹345 cr4.6%6.0%0.0x
2025-0627.8x₹345 cr4.6%6.0%0.0x
2025-0511.3x₹359 cr10.7%28.0%0.0x
2025-0411.7x₹359 cr10.7%28.0%0.0x
2025-0311.4x₹359 cr10.7%28.0%0.0x
2025-027.1x₹364 cr18.0%28.0%0.0x
2025-019.8x₹364 cr18.0%28.0%0.0x
2024-1211.1x₹364 cr18.0%28.0%0.0x
2024-1110.4x₹359 cr18.5%28.0%0.0x
2024-1011.2x₹359 cr18.5%28.0%0.0x
2024-0911.7x₹359 cr18.5%28.0%0.0x
2024-0812.3x₹362 cr19.6%28.0%0.0x
2024-079.7x₹362 cr19.6%28.0%0.0x
2024-0610.3x₹362 cr19.6%28.0%0.0x
2024-0517.7x₹341 cr11.5%17.0%0.0x
2024-0418.9x₹341 cr11.5%17.0%0.0x
2024-0317.0x₹341 cr11.5%17.0%0.0x
2024-0220.6x₹341 cr11.5%17.0%0.0x
2024-0122.6x₹341 cr11.5%17.0%0.0x
2023-1215.4x₹341 cr11.5%17.0%0.0x
2023-1116.7x₹341 cr11.5%17.0%0.0x
2023-1013.1x₹341 cr11.5%17.0%0.0x
2023-0912.2x₹341 cr11.5%17.0%0.0x
2023-0812.6x₹341 cr11.5%17.0%0.0x
2023-0711.7x₹341 cr11.5%17.0%0.0x
2023-069.4x₹341 cr11.5%17.0%0.0x
2023-059.3x₹313 cr12.5%17.0%0.0x
2023-049.8x₹313 cr12.5%17.0%0.0x
2023-038.3x₹313 cr12.5%17.0%0.0x
2023-028.9x₹313 cr12.5%17.0%0.0x
2023-018.9x₹313 cr12.5%17.0%0.0x
2022-129.2x₹313 cr12.5%17.0%0.0x
2022-119.9x₹313 cr12.5%17.0%0.0x
2022-109.0x₹313 cr12.5%17.0%0.0x
2022-099.3x₹313 cr12.5%17.0%0.0x
2022-088.8x₹313 cr12.5%17.0%0.0x
2022-079.2x₹313 cr12.5%17.0%0.0x
2022-068.4x₹313 cr12.5%17.0%0.0x
2022-0513.8x₹246 cr9.0%12.0%0.0x
2022-0415.9x₹246 cr9.0%12.0%0.0x
2022-0313.7x₹246 cr9.0%12.0%0.0x
2022-0213.4x₹246 cr9.0%12.0%0.0x
2022-0117.1x₹246 cr9.0%12.0%0.0x
2021-1215.6x₹246 cr9.0%12.0%0.0x
2021-1114.9x₹246 cr9.0%12.0%0.0x
2021-1014.7x₹246 cr9.0%12.0%0.0x
2021-0915.5x₹246 cr9.0%12.0%0.0x
2021-0814.9x₹246 cr9.0%12.0%0.0x
2021-0714.1x₹246 cr9.0%12.0%0.0x
2021-0612.6x₹246 cr9.0%12.0%0.0x
2021-0513.7x₹320 cr8.5%14.0%0.0x
2021-0413.0x₹320 cr8.5%14.0%0.0x
2021-0311.2x₹320 cr8.5%14.0%0.0x
2021-0212.1x₹320 cr8.5%14.0%0.0x
2021-0112.7x₹320 cr8.5%14.0%0.0x
2020-1213.2x₹320 cr8.5%14.0%0.0x
2020-1113.7x₹320 cr8.5%14.0%0.0x
2020-1011.5x₹320 cr8.5%14.0%0.0x
2020-0913.1x₹320 cr8.5%14.0%0.0x
2020-0812.7x₹320 cr8.5%14.0%0.0x
2020-0712.2x₹320 cr8.5%14.0%0.0x
2020-0612.2x₹320 cr8.5%14.0%0.0x
2020-0510.6x₹316 cr12.8%18.0%0.0x
2020-0410.0x₹316 cr12.8%18.0%0.0x
2020-036.8x₹316 cr12.8%18.0%0.0x
2020-028.7x₹316 cr12.8%18.0%0.0x
2020-0110.2x₹316 cr12.8%18.0%0.0x
2019-128.7x₹316 cr12.8%18.0%0.0x
2019-118.7x₹316 cr12.8%18.0%0.0x
2019-108.5x₹316 cr12.8%18.0%0.0x
2019-097.5x₹316 cr12.8%18.0%0.0x
2019-087.4x₹316 cr12.8%18.0%0.0x
2019-077.8x₹316 cr12.8%18.0%0.0x
2019-068.5x₹316 cr12.8%18.0%0.0x
2019-0525.2x₹285 cr5.4%7.0%0.2x
2019-0422.4x₹285 cr5.4%7.0%0.2x
2019-0322.7x₹285 cr5.4%7.0%0.2x
2019-0222.8x₹285 cr5.4%7.0%0.2x
2019-0121.8x₹285 cr5.4%7.0%0.2x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback